Business
UroGen Pharma Reports First Quarter 2022 Financial Results and Recent Corporate Developments
Jelmyto® net product revenue increased 81% over Q1 2021 to $13.6 million Enrollment of UGN-102 Phase 3 single-arm, ENVISION pivotal trial is ongoing;
About this update from Urogen Pharma Ltd.
[{"type":"text","content":"\n\nJelmyto® net product revenue increased 81% over Q1 2021 to $13.6 million\n\n\nEnrollment of UGN-102 Phase 3 single-arm, ENVISION pivotal trial is ongoing; completion of enrollment expected by end of 2022\n\n\nInitiated novel, multi-arm Phase 1 clinical trial of UGN-301 in high-grade non-muscle invasive bladder cancer (NMIBC)\n\n\nConference call and webcast to be held today at 10:00 AM ET\n\n\n PRINCETON, N.J.--(BUSINESS WIRE)--\nUroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced financial results for the first quarter ended March 31, 2022, and provided an overview of recent developments.\n\n“The first quarter of 2022 saw further commercial, clinical and operational progress as we continued to grow patient access to Jelmyto, advance our clinical-stage candidates and significantly strengthened our financial position in support of our business,” said Liz Barrett, President, and Chief Executive Officer of UroGen. “Thus far in 2022, we have begun enrolling patients in the Phase 3 ENVISION pivotal trial of UGN-102 in low-grade, intermediate-risk NMIBC and initiated a first-in-human, multi-arm Phase 1 clinical study of UGN-301 in high-grade NMIBC. Our accomplishments throughout 2021 and early 2022, coupled with our strengthened balance sheet, position us well to continue to execute on our strategic initiatives as we look to accelerate growth and advance our mission of transforming the treatment paradigm for patients with urothelial cancers.”\n\nBusiness Highlights:\n\nJelmyto (mitomycin) for pyelocalyceal solution in low-grade Upper Tract Urothelial Cancer (LG-UTUC):\n\n\nGenerated net product revenue of $13.6 million for the first quarter of 2022, representing 81% growth over the first quarter of 2021.\n\n\n\nContinued phased launch of uTRACT patient registry intended to evaluate real-world outcomes of LG-UTUC patients treated with Jelmyto, provide insight into long-term treatment benefits, and evaluate its use in clinical practice in the U.S.\n\n\nUGN-102 (mitomycin) for intravesical solution:\n\n\nUroGen began dosing patients in the single-arm Phase 3 ENVISION pivotal trial of UGN-102 for the treatment of low-grade, intermediate-risk NMIBC. The study will enroll approximately 220 patients across 90 sit...